Gyre Therapeutics Inc (GYRE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Gyre Therapeutics Inc (GYRE) is down 19.4% since the beginning of the year. At $6 per share, GYRE is trading 39.6% below its 52-week high of $9. Investors who bought $1,000 worth of GYRE shares 5 years ago would now be looking at an investment worth $555.

Gyre Therapeutics Inc (GYRE) has returned -19.41% so far this year and -30.78% over the past 12 months. Over the last ten years, GYRE has returned -20.75% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Apr 12, 2006, GYRE's average daily return is +0.11%, while the average monthly return is +1.61%. At this rate, an investment would double in approximately 3.6 years.

Historically, 45% of months were positive and 55% were negative. The best month was Jul 2009 with a return of +338.0%, while the worst month was Nov 2021 at -63.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, GYRE closed higher 47% of trading days. The best single day was May 23, 2022 with a return of +234.2%, while the worst single day was Jun 18, 2018 at -63.9%.

Gyre Therapeutics Inc has an annualized alpha of 12.16%, beta of 1.46, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since April 13, 2006.

• This stock participated in 196.46% of S&P 500 Index downside but only 70.15% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GYRE ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Gyre Therapeutics Inc (GYRE) and compare them to S&P 500 Index.

Gyre Therapeutics Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Gyre Therapeutics Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Gyre Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Gyre Therapeutics Inc was 99.98%, occurring on May 13, 2022. The portfolio has not yet recovered.

The current Gyre Therapeutics Inc drawdown is 99.90%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Gyre Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Gyre Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.